{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T03:17:15Z","timestamp":1789010235016,"version":"build-2803163510"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,5,26]],"date-time":"2020-05-26T00:00:00Z","timestamp":1590451200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,5,26]],"date-time":"2020-05-26T00:00:00Z","timestamp":1590451200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Mutations of <jats:italic>ABL1<\/jats:italic> are the dominant mechanism of relapse in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph\u2009+\u2009ALL). We performed highly accurate Duplex Sequencing of exons 4\u201310 of <jats:italic>ABL1<\/jats:italic> on bone marrow or peripheral blood samples from 63 adult patients with previously untreated Ph\u2009+\u2009ALL who received induction with intensive chemotherapy plus a BCR-ABL1 TKI. We identified <jats:italic>ABL1<\/jats:italic> mutations prior to BCR-ABL1 TKI exposure in 78% of patients. However, these mutations were generally present at extremely low levels (median variant allelic frequency 0.008% [range, 0.004%\u20133.71%] and did not clonally expand and lead to relapse in any patient, even when the pretreatment mutation was known to confer resistance to the TKI received. In relapse samples harboring a TKI-resistant <jats:italic>ABL1<\/jats:italic> mutation, the corresponding mutation could not be detected pretreatment, despite validated sequencing sensitivity of Duplex Sequencing down to 0.005%. In samples under the selective pressure of ongoing TKI therapy, we detected low-level, emerging resistance mutations up to 5 months prior to relapse. These findings suggest that pretreatment <jats:italic>ABL1<\/jats:italic> mutation assessment should not guide upfront TKI selection in Ph\u2009+\u2009ALL, although serial testing while on TKI therapy may allow for early detection of clinically actionable resistant clones.<\/jats:p>","DOI":"10.1038\/s41408-020-0329-y","type":"journal-article","created":{"date-parts":[[2020,5,26]],"date-time":"2020-05-26T19:02:59Z","timestamp":1590519779000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Ultra-accurate Duplex Sequencing for the assessment of pretreatment ABL1 kinase domain mutations in Ph+ ALL"],"prefix":"10.1038","volume":"10","author":[{"given":"Nicholas J.","family":"Short","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagop","family":"Kantarjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7829-5249","authenticated-orcid":false,"given":"Rashmi","family":"Kanagal-Shamanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farhad","family":"Ravandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Cortes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Konopleva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4339-8683","authenticated-orcid":false,"given":"Ghayas C.","family":"Issa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5990-9548","authenticated-orcid":false,"given":"Steven M.","family":"Kornblau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Garcia-Manero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Garris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jake","family":"Higgins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Pratt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsey N.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"Charles C.","family":"Valentine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor M.","family":"Rivera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Pritchard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesse J.","family":"Salk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerald","family":"Radich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elias","family":"Jabbour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,5,26]]},"reference":[{"key":"329_CR1","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.clml.2018.05.015","volume":"18","author":"NJ Short","year":"2018","unstructured":"Short, N. J., Kantarjian, H., Pui, C. H., Goldstone, A. & Jabbour, E. SOHO state of the art update and next questions: Philadelphia chromosome-positive acute lymphoblastic leukemia. Clin. Lymphoma Myeloma Leuk. 18, 439\u2013446 (2018).","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"329_CR2","doi-asserted-by":"publisher","first-page":"4158","DOI":"10.1002\/cncr.29646","volume":"121","author":"F Ravandi","year":"2015","unstructured":"Ravandi, F. et al. Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer 121, 4158\u20134164 (2015).","journal-title":"Cancer"},{"key":"329_CR3","doi-asserted-by":"publisher","first-page":"653","DOI":"10.3324\/haematol.2014.118588","volume":"100","author":"N Daver","year":"2015","unstructured":"Daver, N. et al. Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Haematologica 100, 653\u2013661 (2015).","journal-title":"Haematologica"},{"key":"329_CR4","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.leukres.2013.09.011","volume":"38","author":"S Soverini","year":"2014","unstructured":"Soverini, S. et al. Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia. Leuk. Res. 38, 10\u201320 (2014).","journal-title":"Leuk. Res."},{"key":"329_CR5","doi-asserted-by":"publisher","first-page":"6521","DOI":"10.1182\/blood-2011-05-351403","volume":"118","author":"R Foa","year":"2011","unstructured":"Foa, R. et al. Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 118, 6521\u20136528 (2011).","journal-title":"Blood"},{"key":"329_CR6","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1182\/blood-2016-02-700153","volume":"128","author":"P Rousselot","year":"2016","unstructured":"Rousselot, P. et al. Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome-positive ALL. Blood 128, 774\u2013782 (2016).","journal-title":"Blood"},{"key":"329_CR7","doi-asserted-by":"publisher","first-page":"552","DOI":"10.3324\/haematol.2010.034173","volume":"96","author":"S Soverini","year":"2011","unstructured":"Soverini, S. et al. Philadelphia-positive acute lymphoblastic leukemia patients already harbor BCR-ABL kinase domain mutations at low levels at the time of diagnosis. Haematologica 96, 552\u2013557 (2011).","journal-title":"Haematologica"},{"key":"329_CR8","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1038\/leu.2012.5","volume":"26","author":"H Pfeifer","year":"2012","unstructured":"Pfeifer, H. et al. Prevalence and dynamics of bcr-abl kinase domain mutations during imatinib treatment differ in patients with newly diagnosed and recurrent bcr-abl positive acute lymphoblastic leukemia. Leukemia 26, 1475\u20131481 (2012).","journal-title":"Leukemia"},{"key":"329_CR9","doi-asserted-by":"publisher","first-page":"2298","DOI":"10.3109\/10428194.2016.1144881","volume":"57","author":"R DeBoer","year":"2016","unstructured":"DeBoer, R. et al. Clinical impact of ABL1 kinase domain mutations and IKZF1 deletion in adults under age 60 with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL): molecular analysis of CALGB (Alliance) 10001 and 9665. Leuk. Lymphoma 57, 2298\u20132306 (2016).","journal-title":"Leuk. Lymphoma"},{"key":"329_CR10","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.3390\/v1031137","volume":"1","author":"L Menendez-Arias","year":"2009","unstructured":"Menendez-Arias, L. Mutation rates and intrinsic fidelity of retroviral reverse transcriptases. Viruses 1, 1137\u20131165 (2009).","journal-title":"Viruses"},{"key":"329_CR11","doi-asserted-by":"publisher","first-page":"5321","DOI":"10.1158\/1078-0432.CCR-18-0167","volume":"24","author":"MW Schmitt","year":"2018","unstructured":"Schmitt, M. W. et al. Single-molecule sequencing reveals patterns of preexisting drug resistance that suggest treatment strategies in philadelphia-positive leukemias. Clin. Cancer Res. 24, 5321\u20135334 (2018).","journal-title":"Clin. Cancer Res."},{"key":"329_CR12","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/nmeth.3351","volume":"12","author":"MW Schmitt","year":"2015","unstructured":"Schmitt, M. W. et al. Sequencing small genomic targets with high efficiency and extreme accuracy. Nat. Methods. 12, 423\u2013425 (2015).","journal-title":"Nat. Methods."},{"key":"329_CR13","doi-asserted-by":"publisher","first-page":"14508","DOI":"10.1073\/pnas.1208715109","volume":"109","author":"MW Schmitt","year":"2012","unstructured":"Schmitt, M. W. et al. Detection of ultra-rare mutations by next-generation sequencing. Proc. Natl Acad. Sci. USA 109, 14508\u201314513 (2012).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"329_CR14","doi-asserted-by":"publisher","first-page":"e618","DOI":"10.1016\/S2352-3026(18)30176-5","volume":"5","author":"E Jabbour","year":"2018","unstructured":"Jabbour, E. et al. Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study. Lancet Haematol. 5, e618\u2013e627 (2018).","journal-title":"Lancet Haematol."},{"key":"329_CR15","doi-asserted-by":"publisher","first-page":"2586","DOI":"10.1038\/nprot.2014.170","volume":"9","author":"SR Kennedy","year":"2014","unstructured":"Kennedy, S. R. et al. Detecting ultralow-frequency mutations by Duplex Sequencing. Nat. Protoc. 9, 2586\u20132606 (2014).","journal-title":"Nat. Protoc."},{"key":"329_CR16","doi-asserted-by":"publisher","first-page":"E125","DOI":"10.1002\/ajh.23338","volume":"87","author":"S Redaelli","year":"2012","unstructured":"Redaelli, S. et al. Three novel patient-derived BCR\/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors. Am. J. Hematol. 87, E125\u2013E128 (2012).","journal-title":"Am. J. Hematol."},{"key":"329_CR17","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1111\/j.1349-7006.2010.01627.x","volume":"101","author":"CC Yin","year":"2010","unstructured":"Yin, C. C. et al. Rapid clonal shifts in response to kinase inhibitor therapy in chronic myelogenous leukemia are identified by quantitation mutation assays. Cancer Sci. 101, 2005\u20132010 (2010).","journal-title":"Cancer Sci."},{"key":"329_CR18","doi-asserted-by":"publisher","first-page":"4005","DOI":"10.1182\/blood-2007-03-080838","volume":"110","author":"J Cortes","year":"2007","unstructured":"Cortes, J. et al. Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors. Blood. 110, 4005\u20134011 (2007).","journal-title":"Blood."},{"key":"329_CR19","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1200\/JCO.2008.19.8853","volume":"27","author":"S Redaelli","year":"2009","unstructured":"Redaelli, S. et al. Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR\/ABL mutants. J. Clin. Oncol. 27, 469\u2013471 (2009).","journal-title":"J. Clin. Oncol."},{"key":"329_CR20","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.hoc.2017.04.007","volume":"31","author":"AB Patel","year":"2017","unstructured":"Patel, A. B., O\u2019Hare, T. & Deininger, M. W. Mechanisms of resistance to ABL kinase inhibition in chronic myeloid leukemia and the development of next generation ABL kinase inhibitors. Hematol. Oncol. Clin. North Am. 31, 589\u2013612 (2017).","journal-title":"Hematol. Oncol. Clin. North Am."},{"key":"329_CR21","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1021\/bi00119a002","volume":"31","author":"JP Ji","year":"1992","unstructured":"Ji, J. P. & Loeb, L. A. Fidelity of HIV-1 reverse transcriptase copying RNA in vitro. Biochemistry 31, 954\u2013958 (1992).","journal-title":"Biochemistry"},{"key":"329_CR22","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.beha.2017.05.001","volume":"30","author":"NJ Short","year":"2017","unstructured":"Short, N. J., Kantarjian, H., Jabbour, E. & Ravandi, F. Which tyrosine kinase inhibitor should we use to treat Philadelphia chromosome-positive acute lymphoblastic leukemia? Best Pract. Res. Clin. Haematol. 30, 193\u2013200 (2017).","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"329_CR23","doi-asserted-by":"publisher","first-page":"3650","DOI":"10.1002\/cncr.30231","volume":"122","author":"K Sasaki","year":"2016","unstructured":"Sasaki, K. et al. Hyper-CVAD plus ponatinib versus hyper-CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: a propensity score analysis. Cancer 122, 3650\u20133656 (2016).","journal-title":"Cancer"},{"key":"329_CR24","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.freeradbiomed.2010.05.008","volume":"49","author":"Z Radak","year":"2010","unstructured":"Radak, Z. & Boldogh, I. 8-Oxo-7,8-dihydroguanine: links to gene expression, aging, and defense against oxidative stress. Free Radic. Biol. Med. 49, 587\u2013596 (2010).","journal-title":"Free Radic. Biol. Med."},{"issue":"Supplement_1","key":"329_CR25","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1182\/blood-2019-124029","volume":"134","author":"J-M Cayuela","year":"2019","unstructured":"Cayuela, J.-M. et al. Sensitive monitoring of BCR-ABL1 kinase domain mutations by next generation sequencing for optimizing clinical decisions in philadelphia-positive acute lymphoblastic leukemia in the graaph-2014 trial. Blood 134(Supplement_1), 1295\u20131295 (2019).","journal-title":"Blood"},{"key":"329_CR26","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/nrclinonc.2015.175","volume":"13","author":"MW Schmitt","year":"2016","unstructured":"Schmitt, M. W., Loeb, L. A. & Salk, J. J. The influence of subclonal resistance mutations on targeted cancer therapy. Nat. Rev. Clin. Oncol. 13, 335\u2013347 (2016).","journal-title":"Nat. Rev. Clin. Oncol."}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-020-0329-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-020-0329-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-020-0329-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T14:28:39Z","timestamp":1670250519000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-020-0329-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,26]]},"references-count":26,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2020,5]]}},"alternative-id":["329"],"URL":"https:\/\/doi.org\/10.1038\/s41408-020-0329-y","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,26]]},"assertion":[{"value":"25 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"N.J.S. reports consulting fees from Takeda Oncology and AstraZeneca, research funding from Takeda Oncology and Astellas Pharma Inc., and honoraria from Amgen. F.R. reports research funding from Bristol-Myers Squibb and honoraria from Bristol-Myers Squibb, Novartis and Pfizer. J.H., G.P., L.N.W., C.C.V., and J.J.S. are employees and equity holders of TwinStrand Biosciences Inc., which performed Duplex Sequencing. V.M.R. reports employment, stock, and other ownership interests in ARIAD Pharmaceuticals Inc. The other authors report no relevant conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"61"}}